# A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

> **NCT01593137** · PHASE4 · WITHDRAWN · sponsor: **Fundación Fernández-Cruz**

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Liraglutide + metformin
- **DRUG:** Glimepiride + metformin

## Key facts

- **NCT ID:** NCT01593137
- **Lead sponsor:** Fundación Fernández-Cruz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-05
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of patients with the criteria established in the protocol.
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593137, "A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01593137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*